Maria Taboada
Overview
Explore the profile of Maria Taboada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez-Prieto M, Moreira C, Cruz S, Campos V, Martinez-Regueiro R, Taboada M, et al.
J Autism Dev Disord
. 2020 Sep;
51(6):2091-2103.
PMID: 32915356
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interaction, executive functioning, sensory-perceptual abilities and behaviour, such as anxious/depressed states, attention problems, aggression, or somatic complains....
2.
Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al.
J Thorac Oncol
. 2019 Oct;
15(2):288-293.
PMID: 31622733
Introduction: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of...
3.
Baverel P, Roskos L, Tatipalli M, Lee N, Stockman P, Taboada M, et al.
Clin Transl Sci
. 2019 Mar;
12(5):450-458.
PMID: 30883000
Tremelimumab, an anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that enhances T-cell activation, was evaluated in a randomized, double-blind, placebo-controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study...
4.
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al.
N Engl J Med
. 2018 Oct;
379(24):2342-2350.
PMID: 30280658
Background: An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC)...
5.
Maarouf H, Taboada M, Rodriguez H, Arias M, Sesar A, Sobrido M
BMC Med Inform Decis Mak
. 2017 Dec;
17(1):159.
PMID: 29207981
Background: Electronic rating scales represent an important resource for standardized data collection. However, the ability to exploit reasoning on rating scale data is still limited. The objective of this work...
6.
Taboada M, Rodriguez H, Gudivada R, Martinez D
BMC Bioinformatics
. 2017 Oct;
18(1):446.
PMID: 29017443
Background: Named entity recognition is critical for biomedical text mining, where it is not unusual to find entities labeled by a wide range of different terms. Nowadays, ontologies are one...
7.
Maio M, Scherpereel A, Calabro L, Aerts J, Perez S, Bearz A, et al.
Lancet Oncol
. 2017 Jul;
18(9):1261-1273.
PMID: 28729154
Background: New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with...
8.
Taboada M, Melnick D, Iaconis J, Sun F, Zhong N, File T, et al.
J Antimicrob Chemother
. 2016 Apr;
71(6):1748-9.
PMID: 27076104
No abstract available.
9.
Taboada M, Melnick D, Iaconis J, Sun F, Zhong N, File T, et al.
J Antimicrob Chemother
. 2015 Dec;
71(4):862-70.
PMID: 26702925
Background: We conducted a meta-analysis of clinical trials of adults hospitalized with pneumonia outcomes research team (PORT) risk class 3-4 community-acquired pneumonia (CAP) receiving ceftaroline fosamil versus ceftriaxone. Methods: Three...
10.
Taboada M, Rodriguez H, Martinez D, Pardo M, Sobrido M
Database (Oxford)
. 2015 Nov;
2015.
PMID: 26568328
No abstract available.